CPS

Triple-Negative Breast Cancer (TNBC)

Indication-specific training resources to support high-quality diagnostic assessment of TNBC specimens stained with PD-L1 IHC 22C3 pharmDx.

 

PD-L1 IHC 22C3 pharmDx Interpretation Training Program for Triple-Negative Breast Cancer (TNBC)

View More

PD-L1 IHC 22C3 pharmDx Interpretation Manual for Triple-Negative Breast Cancer (TNBC)

View More

PD-L1 IHC 22C3 pharmDx Quick Scoring Guide for Triple-Negative Breast Cancer (TNBC)

View More

PD-L1 Staining Immune and Tumor Cells in a Triple-Negative Breast Cancer (TNBC) case

View More

PD-L1 Staining Stromal Cells in a Triple-Negative Breast Cancer (TNBC) Case

View More

PD-L1 Staining in a Heterogenous Triple-Negative Breast Cancer (TNBC) Case

View More

The PD-1/PD-L1 Pathway

View More

The development of a CDx IHC Assay

View More

What is a CDx IHC Assay?

View More

Advanced Tutorial: Quantifying Tumor Cells in Cases with Challenging Histology

View More

Scoring Near the CPS Cutoffs: Real-World Approaches

View More

Applying The 20X Rule for Scoring CPS

View More

Efficiently Evaluating the CPS Denominator

View More

Confidence in Evaluating Combined Positive Score: How a Systematic Approach Can Simplify PD-L1 Scoring with CPS

View More

Scoring of Triple-Negative Breast Cancer (TNBC): Example Cases from PD-L1 IHC 22C3 pharmDx Atlas of Stain

View More

Assessing PD-L1 Combined Positive Score (CPS) in Various Tumor Types with Distinct Morphological Characteristics

View More

The Nuances of Tumor Types: How are Cutoffs Determined and Validated?

View More

Implementation of PD-L1 Testing in the New Era of an Everchanging Immuno-oncology Landscape

View More

Mastering Combined Positive Score (CPS) From Principles to Real-world Applications

View More

The Pathologist and the Oncologist Working Together on PD-L1 to Improve Patient Treatment

View More

External Quality Assurance of PD-L1 Assays The NordiQC Experience

View More

The Rationale Behind the Scoring Systems for PD-L1 IHC to Determine Patients Eligible for KEYTRUDA (pembrolizumab)

View More

The Value of CDx IHC Assays in the Complex Environment of PD‑L1 Testing

View More

D72740_01